Novartis to buy radiology specialist Mariana Oncology for US$1 billion
Mariana Oncology is a preclinical-stage biotechnology company focused on developing novel radioligand therapies to treat cancers
Novartis has entered an agreement to acquire US radiopharmaceutical company Mariana Oncology for US$1 billion, boosting its portfolio of cancer treatments in development, the Swiss drug manufacturer said on Thursday (May 2).
The deal also includes US$750 million of potential further payments upon achieving certain milestones, it added.
Mariana Oncology is a preclinical-stage biotechnology company focused on developing novel radioligand therapies (RLTs) to treat cancers.
“The transaction bolsters the Novartis RLT pipeline and expands the company’s research infrastructure and clinical supply capabilities,” Novartis said in a statement.
Novartis has been cutting jobs and costs, and spun off its generic drugs business Sandoz last year, part of a focus on fewer therapeutic areas and geographic markets.
In February, it struck a deal to buy German cancer drug developer MorphoSys for US$2.89 billion. REUTERS
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Stocks to watch: NetLink NBN Trust, Centurion, No Signboard
Haidilao restaurant operator Super Hi prices US IPO at US$19.56 per share
Chinese EV giants hammered by Biden tariff are welcome in Brazil
Hong Kong’s shaky crypto ETF debuts dent global hub aspirations
OpenAI, Reddit sign partnership on ChatGPT, AI products, ads
US Fed officials suggest interest rates should stay high for longer